Products for Research Use Only

Droloxifene

CAT: 0804-HY-121149-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-121149-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats [1][2][3].
CAS Number
82413-20-5
Product Name Alternative
3-Hydroxytamoxifen
UNSPSC
12352005
Hazard Statement
H317, H351, H360, H410
Target
Apoptosis; Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Apoptosis; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/droloxifene.html
Concentration
10mM
Purity
99.89
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC1=CC=CC(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CC)=C1
Molecular Formula
C26H29NO2
Molecular Weight
387.51
Precautions
H317, H351, H360, H410
References & Citations
[1]Herrington DM, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthypostmenopausal women. Arterioscler Thromb Vasc Biol. 2000 Jun;20 (6) :1606-12.|[2]Grasser WA, et al. Common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cell Biochem. 1997 May;65 (2) :159-71.|[3]Ke HZ, et al. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. ndocrinology. 1995 Jun;136 (6) :2435-41.|[4]Huang Y, et al. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta Pharmacol Sin. 2005 Oct;26 (10) :1243-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products